Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 65Neoplasms 10Neoplasm Metastasis 9Kidney Neoplasms 7Prostatic Neoplasms 5Urinary Bladder Neoplasms 4Sarcoma 4Clear-cell metastatic renal cell carcinoma 4Breast Neoplasms 4Pancreatic Neoplasms 3Ovarian Neoplasms 3Melanoma 2Financial Stress 2Carcinoma, Non-Small-Cell Lung 2Wilms Tumor 1Uterine Cervical Neoplasms 1Urethral Neoplasms 1Thyroid Neoplasms 1Testicular Neoplasms 1Small Cell Lung Carcinoma 1Patient Preference 1Pathologic Complete Response 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Osteosarcoma 1Oncocytoma, renal 1Neuroblastoma 1Neoplasms, Plasma Cell 1Neoplasms, Germ Cell and Embryonal 1Lung Neoplasms 1Liver Neoplasms 1

Interventions

Cisplatin 3Etoposide 2Bleomycin 2Amifostine 2pazopanib 1glucarpidase 1Social Determinants of Health 1Methotrexate 1Gemcitabine 1Chemotherapy, Adjuvant 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Drug-Related Side Effects and Adverse Reactions × pazopanib × Genitourinary × Clear all
NCT02324803 2014-12-24

Phase II Study of Pazopanib as Second-line Treatment After Sunitinib in mRCC Patients

Southern China Urology Cancer Consortium

Phase 2 Unknown
86 enrolled
Genitourinary

Carcinoma, Renal Cell, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡